Скачать с ютуб JP Morgan Week 2025 – Ryan Spencer в хорошем качестве

JP Morgan Week 2025 – Ryan Spencer

COVID-19 raised the public awareness of vaccines, but also of vaccine denialism and conspiracy theories. But for the companies building and selling new vaccines, all that fades into the background of the work: creating safer and more effective vaccines. At JP Morgan 2025, pharmaphorum editor-in-chief Jonah Comstock spoke with Ryan Spencer, whose company Dynavax technologies is in the market with an adult hepatitis B vaccine and recently completed enrolment for its shingles vaccine trial. Spencer discusses the CPG 1018 adjuvant that his biotech is leveraging to create vaccines with a higher tolerability profile. They also discuss the larger political and social climate around vaccination and the steps being taken toward the development of a universal flu and COVID vaccine. Tune in below for all that, plus some discussion of the dealmaking environment and how it affects companies like Dynavax. Follow @pharmaphorum for more news, insights, and industry analysis.